A Phase 4 interventional study of Ticagrelor in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 39 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-04-03.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 12th largest by enrollment, is one of 8 that started in 2013, is one of 38 in phase 4, and was the 15th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
Fu Wai Hospital, Beijing, China · Sites in China
Ages 18+
Shanghai Tong Ren Hospital · Sites in China
Ages 75+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 38
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,004 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 120 across the 67 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
36 studies in Acute Coronary Syndrome by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 8 (23%) have results posted.
Among the 36 studies in Acute Coronary Syndrome by AstraZeneca, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2013, is one of 5 in phase 4, and was the 19th registered.
AstraZeneca’s Acute Coronary Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 36 in Acute Coronary Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
90 mg/tablet, 1 tablet bid
Drug: Ticagrelor
90mg/tablet, 1 tablet bid
Bleeding Events
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal
Time frame: 12 months
Serious Adverse Events Other Than Bleeding
SAEs except the blending events which have aleady been reported as SAEs.
Time frame: 12 months
Major CV Events
Combination of CV death, MI, and stroke
Time frame: 12 months
| Milestone | Ticargrelor |
|---|---|
| Started | 2004 |
| Completed | 1914 |
| Not completed | 90 |
| Withdrew: Subject decision | 80 |
| Withdrew: Severe non-compliance to protocol | 7 |
| Withdrew: Subject lost to follow up | 2 |
| Withdrew: Other | 1 |
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal
| Participants | Ticargrelor |
|---|---|
| Fatal/life threatening | 17 |
| Major | 27 |
| Major + minor | 93 |
| Major + minor + minimal | 426 |
SAEs except the blending events which have aleady been reported as SAEs.
| Participants | Ticargrelor |
|---|---|
| Serious Adverse Events Other Than Bleeding | 116 |
Combination of CV death, MI, and stroke
| Participants | Ticargrelor |
|---|---|
| Major CV Events | 85 |
Collected over From day of first dose to the day of last dose + 7 days, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticargrelor | — | 161/2,001 (8%) | 230/2,001 (11.5%) |
| Event | Ticargrelor |
|---|---|
| Upper Gastrointestinal HaemorrhageGastrointestinal disorders | 16/2001 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 12/2001 |
| Chest DiscomfortGeneral disorders | 6/2001 |
| Cardiac FailureCardiac disorders | 5/2001 |
| GastritisGastrointestinal disorders | 4/2001 |
| Lung InfectionInfections and infestations | 4/2001 |
| Chronic Kidney DiseaseRenal and urinary disorders | 4/2001 |
| HaematuriaRenal and urinary disorders | 4/2001 |
| Cerebral HaemorrhageNervous system disorders | 4/2001 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 4/2001 |
| Event | Ticargrelor |
|---|---|
| HyperuricaemiaMetabolism and nutrition disorders | 130/2001 |
| EcchymosisSkin and subcutaneous tissue disorders | 113/2001 |
Based on the safety population, i.e. all enrolled patients who received at least one dose of Investigational product (IP)
| Age, Continuous(Years) | Ticargrelor |
|---|---|
| Mean | 59.3 ± 10.83 |
| Age, Customized(Participants) | Ticargrelor |
|---|---|
| < 75 years | 1854 |
| >= 75 years | 147 |
| Sex: Female, Male(Participants) | Ticargrelor |
|---|---|
| Female | 422 |
| Male | 1579 |
| Race/Ethnicity, Customized(Participants) | Ticargrelor |
|---|---|
| Hispanic or latino | 0 |
| Not hispanic or latino | 2001 |
| Race/Ethnicity, Customized(Participants) | Ticargrelor |
|---|---|
| Asian | 2001 |
| Other | 0 |
Ran from Jun 2013 to primary completion in Sep 2015, 27 months.
Results were first posted in Nov 2016, 1 year 1 month after primary completion.
Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor